4D Molecular CEO sells 12,415 shares under plan

Accepted by SEC EDGAR 08/04/2026 - 04:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. President and Chief Executive Officer David Kirn sold 12,415 shares of common stock on August 3, 2026 at a weighted average price of $10.0461 per share, pursuant to a 10b5-1 trading plan adopted January 9, 2026, and now directly holds 871,737 shares.

Insider Trade Summary 10b5-1

Net Seller: 12,415 shares

Net Sell 1 txn

Insider Kirn David

Role See Remarks

Sold 12,415 shs ($125K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	12,415	$10.0461	$125K

Holdings After Transaction: Common Stock — 871,737 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
2. F2. The transaction was executed in multiple trades in prices ranging from $10.00 to $10.1250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 12,415 shares Weighted average sale price: $10.0461 per share Shares held after sale: 871,737 shares +2 more

5 metrics

Shares sold 12,415 shares Common stock sale by David Kirn on August 3, 2026

Weighted average sale price $10.0461 per share Average price for the August 3, 2026 common stock sale

Shares held after sale 871,737 shares Common stock directly owned by David Kirn after the reported transaction

Price range of trades $10.00 to $10.1250 per share Range of prices for the multiple trades comprising the reported sale

10b5-1 plan adoption date January 9, 2026 Date David Kirn adopted the trading plan governing the August 3, 2026 sale

Key Terms

10b5-1 trading plan, weighted average sale price, open market or private transaction

3 terms

10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price."

open market or private transaction market

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 4D Molecular Therapeutics (FDMT) report for David Kirn?

David Kirn sold 12,415 shares of 4D Molecular Therapeutics common stock on August 3, 2026. The sale was executed at a weighted average price of $10.0461 per share under a 10b5-1 trading plan, leaving him with 871,737 shares directly held.

At what price did David Kirn sell his FDMT shares?

The reported weighted average sale price was $10.0461 per share. The transaction was executed in multiple trades at prices ranging from $10.00 to $10.1250 per share, with the average reported as the sale price for this transaction.

How many FDMT shares does David Kirn hold after this sale?

After the transaction, David Kirn directly holds 871,737 shares of 4D Molecular Therapeutics common stock. This figure reflects his position following the 12,415-share sale reported for August 3, 2026, and represents his directly owned holdings only.

Was David Kirn’s FDMT stock sale made under a 10b5-1 trading plan?

Yes. The sale was made pursuant to a 10b5-1 trading plan adopted by David Kirn on January 9, 2026. Such plans allow pre-arranged trading of shares according to set instructions, which can limit the informational value of trade timing.

What role does David Kirn hold at 4D Molecular Therapeutics (FDMT)?

David Kirn is the President and Chief Executive Officer of 4D Molecular Therapeutics and also serves as a director. His reported stock sale and resulting holdings therefore relate to an executive and board-level insider of the company.

What type of transaction was David Kirn’s FDMT share sale?

The transaction is classified as a sale of common stock coded as “S,” described as a sale in an open market or private transaction. It involved non-derivative securities and resulted in updated directly owned common stock holdings for David Kirn.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirn David

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S(1)		12,415	D	$10.0461(2)	871,737	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

2. The transaction was executed in multiple trades in prices ranging from $10.00 to $10.1250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President and Chief Executive Officer

	/s/ Scott Bizily as Attorney-in-Fact for David Kirn	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)